Literature DB >> 24677692

Discovery of 5-(2-(phenylamino)pyrimidin-4-yl)thiazol-2(3H)-one derivatives as potent Mnk2 inhibitors: synthesis, SAR analysis and biological evaluation.

Sarah Diab1, Theodosia Teo, Malika Kumarasiri, Peng Li, Mingfeng Yu, Frankie Lam, Sunita K C Basnet, Matthew J Sykes, Hugo Albrecht, Robert Milne, Shudong Wang.   

Abstract

Phosphorylation of eIF4E by human mitogen-activated protein kinase (MAPK)-interacting kinases (Mnks) is crucial for human tumourigenesis and development. Targeting Mnks may provide a novel anticancer therapeutic strategy. However, the lack of selective Mnk inhibitors has so far hampered pharmacological target validation and clinical drug development. Herein, we report, for the first time, the discovery of a series of 5-(2-(phenylamino)pyrimidin-4-yl)thiazole-2(3H)-one derivatives as Mnk inhibitors. Several derivatives demonstrate very potent Mnk2 inhibitory activity. The most active and selective compounds were tested against a panel of cancer cell lines, and the results confirm the cell-type-specific effect of these Mnk inhibitors. Detailed cellular mechanistic studies reveal that Mnk inhibitors are capable of reducing the expression level of anti-apoptotic protein Mcl-1, and of promoting apoptosis in MV4-11 acute myeloid leukaemia cells.
© 2014 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.

Entities:  

Keywords:  CGP57380; Mnk inhibitors; anticancer drug discovery; apoptosis; eIF4E phosphorylation

Mesh:

Substances:

Year:  2014        PMID: 24677692     DOI: 10.1002/cmdc.201300552

Source DB:  PubMed          Journal:  ChemMedChem        ISSN: 1860-7179            Impact factor:   3.466


  16 in total

1.  CDKI-73: an orally bioavailable and highly efficacious CDK9 inhibitor against acute myeloid leukemia.

Authors:  Muhammed H Rahaman; Yingyi Yu; Longjin Zhong; Julian Adams; Frankie Lam; Peng Li; Ben Noll; Robert Milne; Jun Peng; Shudong Wang
Journal:  Invest New Drugs       Date:  2018-09-08       Impact factor: 3.850

Review 2.  Targeting the translation machinery in cancer.

Authors:  Mamatha Bhat; Nathaniel Robichaud; Laura Hulea; Nahum Sonenberg; Jerry Pelletier; Ivan Topisirovic
Journal:  Nat Rev Drug Discov       Date:  2015-03-06       Impact factor: 84.694

Review 3.  Targeting the eIF4F translation initiation complex: a critical nexus for cancer development.

Authors:  Jerry Pelletier; Jeremy Graff; Davide Ruggero; Nahum Sonenberg
Journal:  Cancer Res       Date:  2015-01-15       Impact factor: 12.701

Review 4.  Targeting mTOR signaling pathways and related negative feedback loops for the treatment of acute myeloid leukemia.

Authors:  Benedito A Carneiro; Jason B Kaplan; Jessica K Altman; Francis J Giles; Leonidas C Platanias
Journal:  Cancer Biol Ther       Date:  2015       Impact factor: 4.742

5.  Discovery of novel Mnk inhibitors using mutation-based induced-fit virtual high-throughput screening.

Authors:  Rama K Mishra; Matthew R Clutter; Gavin T Blyth; Ewa M Kosciuczuk; Amy Z Blackburn; Elspeth M Beauchamp; Gary E Schiltz; Leonidas C Platanias
Journal:  Chem Biol Drug Des       Date:  2019-08-04       Impact factor: 2.817

Review 6.  Dual targeting of eIF4E by blocking MNK and mTOR pathways in leukemia.

Authors:  Ewa M Kosciuczuk; Diana Saleiro; Leonidas C Platanias
Journal:  Cytokine       Date:  2016-04-16       Impact factor: 3.861

Review 7.  Phosphorylation of the mRNA cap-binding protein eIF4E and cancer.

Authors:  Xiaotong Yang; Wu Zhong; Ruifeng Cao
Journal:  Cell Signal       Date:  2020-06-11       Impact factor: 4.315

8.  New pyridine and chromene scaffolds as potent vasorelaxant and anticancer agents.

Authors:  Dina H Dawood; Aladdin M Srour; Dalia O Saleh; Kelley J Huff; Francesca Greco; Helen M I Osborn
Journal:  RSC Adv       Date:  2021-09-02       Impact factor: 3.361

9.  Targeting RNA transcription and translation in ovarian cancer cells with pharmacological inhibitor CDKI-73.

Authors:  Frankie Lam; Abdullahi Y Abbas; Hao Shao; Theodosia Teo; Julian Adams; Peng Li; Tracey D Bradshaw; Peter M Fischer; Elisabeth Walsby; Chris Pepper; Yi Chen; Jian Ding; Shudong Wang
Journal:  Oncotarget       Date:  2014-09-15

Review 10.  Signalling to eIF4E in cancer.

Authors:  Nadeem Siddiqui; Nahum Sonenberg
Journal:  Biochem Soc Trans       Date:  2015-10       Impact factor: 5.407

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.